{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-25-000428","form_type":"8-K","ticker":"BDPT","cik":"0001575142","company_name":"BIOADAPTIVES, INC.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.044779+00:00","generated_at":"2026-05-24T13:39:44.381817+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioAdaptives' Zeranovia weight loss product shows 5-7 lbs/week loss in dosage trial","bullets":["Participants lost 5–7 pounds per week in Zeranovia dosage trial.","Minimal side effects: mild GI discomfort manageable by increasing water intake or adjusting dosage.","All trial subjects requested to proceed to next phase, indicating high satisfaction.","Company advancing to dosage adjustments for next-stage clinical trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-25-000428","json":"https://secwatch.observer/filing/0001640334-25-000428.json","markdown":"https://secwatch.observer/filing/0001640334-25-000428.md","text":"https://secwatch.observer/filing/0001640334-25-000428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1575142/000164033425000428/0001640334-25-000428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1575142/000164033425000428/bdpt_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T13:39:44.381817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}